235 related articles for article (PubMed ID: 18334033)
1. Transient T cell depletion causes regression of melanoma metastases.
Rasku MA; Clem AL; Telang S; Taft B; Gettings K; Gragg H; Cramer D; Lear SC; McMasters KM; Miller DM; Chesney J
J Transl Med; 2008 Mar; 6():12. PubMed ID: 18334033
[TBL] [Abstract][Full Text] [Related]
2. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.
Telang S; Rasku MA; Clem AL; Carter K; Klarer AC; Badger WR; Milam RA; Rai SN; Pan J; Gragg H; Clem BF; McMasters KM; Miller DM; Chesney J
BMC Cancer; 2011 Dec; 11():515. PubMed ID: 22165955
[TBL] [Abstract][Full Text] [Related]
4. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
Mahnke K; Schönfeld K; Fondel S; Ring S; Karakhanova S; Wiedemeyer K; Bedke T; Johnson TS; Storn V; Schallenberg S; Enk AH
Int J Cancer; 2007 Jun; 120(12):2723-33. PubMed ID: 17315189
[TBL] [Abstract][Full Text] [Related]
5. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.
Baur AS; Lutz MB; Schierer S; Beltrame L; Theiner G; Zinser E; Ostalecki C; Heidkamp G; Haendle I; Erdmann M; Wiesinger M; Leisgang W; Gross S; Pommer AJ; Kämpgen E; Dudziak D; Steinkasserer A; Cavalieri D; Schuler-Thurner B; Schuler G
Blood; 2013 Sep; 122(13):2185-94. PubMed ID: 23958949
[TBL] [Abstract][Full Text] [Related]
6. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
7. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
Gritzapis AD; Voutsas IF; Baxevanis CN
Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
[TBL] [Abstract][Full Text] [Related]
8. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
[TBL] [Abstract][Full Text] [Related]
9. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
12. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
[TBL] [Abstract][Full Text] [Related]
13. Depletion of human regulatory T cells.
Hobeika AC; Morse MA; Osada T; Peplinski S; Lyerly HK; Clay TM
Methods Mol Biol; 2011; 707():219-31. PubMed ID: 21287338
[TBL] [Abstract][Full Text] [Related]
14. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
16. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
Dannull J; Su Z; Rizzieri D; Yang BK; Coleman D; Yancey D; Zhang A; Dahm P; Chao N; Gilboa E; Vieweg J
J Clin Invest; 2005 Dec; 115(12):3623-33. PubMed ID: 16308572
[TBL] [Abstract][Full Text] [Related]
18. Comparative methodologies of regulatory T cell depletion in a murine melanoma model.
Matsushita N; Pilon-Thomas SA; Martin LM; Riker AI
J Immunol Methods; 2008 Apr; 333(1-2):167-79. PubMed ID: 18295790
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
[TBL] [Abstract][Full Text] [Related]
20. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Powell DJ; Felipe-Silva A; Merino MJ; Ahmadzadeh M; Allen T; Levy C; White DE; Mavroukakis S; Kreitman RJ; Rosenberg SA; Pastan I
J Immunol; 2007 Oct; 179(7):4919-28. PubMed ID: 17878392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
